Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210369070> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4210369070 endingPage "62" @default.
- W4210369070 startingPage "59" @default.
- W4210369070 abstract "Introduction: Cervical cancer, on a global forum stands third most commonly diagnosed cancer. It is the fourth leading cause of cancer death in women. Despite with treatment of surgery, radiation and or chemotherapy, cervical cancer may persist or recur months or years after completion of initial treatment. Recently, the epidermal growth factor receptor (EGFR; HER1/erbB- 1) has been recognized as target for cancer therapy in numerous cancers. Clinical trials have demonstrated that only a subset of patients respond to EGFR inhibitors. Therefore the present study aimed to study the response rate of the drug gefitinib in patients receiving cisplatin-based chemotherapy in cervical cancer. Methods: Study was a randomized prospective study. Patients were randomized into two arms in the ratio 2:1 to get a statistically significant result. The sample size (n) was 16 in the experiment arm (Gefitinib+ Cisplatin) and 32 in the control (Cisplatin) arm. Toxicity and Response rate was assessed during the treatment, one month and 3 months post treatment. Results: A total of 23 subjects were included in the final analysis. On cisplatin were 16 (69.6%) and on Cisplatin+Gefitinib were 7 (30.4%). Our study attempted to evaluate the response rate and safety of gefitinib drug on locally advance cervical cancerous growth among 16 subjects, but because of the toxicity we couldn’t complete the study. Gefitinib was found to cause severe adverse drug reactions like grade 3 diarrhoea, fall in haemoglobin in many patients. Response rate was found to be satisfactory in both the arms. Conclusion: Due to overall small sample size, patients lost during treatment and unequal sample among the cisplatin and cisplatin +gefitinib group the analysis of disease-free period, adverse events could not be analysed. The efficacy of gefitinib among cervical patients was inconclusive and warrants further research in future." @default.
- W4210369070 created "2022-02-08" @default.
- W4210369070 creator A5004891537 @default.
- W4210369070 creator A5009884031 @default.
- W4210369070 creator A5061084965 @default.
- W4210369070 creator A5067700000 @default.
- W4210369070 creator A5072659641 @default.
- W4210369070 date "2022-01-30" @default.
- W4210369070 modified "2023-09-30" @default.
- W4210369070 title "A Prospective Randomised Open Label Study to Evaluate the Response Rate and Toxicity of Gefitinib in the Treatment of Carcinoma Cervix Patients on Chemoradiotherapy" @default.
- W4210369070 doi "https://doi.org/10.5530/jcram.1.2.14" @default.
- W4210369070 hasPublicationYear "2022" @default.
- W4210369070 type Work @default.
- W4210369070 citedByCount "0" @default.
- W4210369070 crossrefType "journal-article" @default.
- W4210369070 hasAuthorship W4210369070A5004891537 @default.
- W4210369070 hasAuthorship W4210369070A5009884031 @default.
- W4210369070 hasAuthorship W4210369070A5061084965 @default.
- W4210369070 hasAuthorship W4210369070A5067700000 @default.
- W4210369070 hasAuthorship W4210369070A5072659641 @default.
- W4210369070 hasBestOaLocation W42103690701 @default.
- W4210369070 hasConcept C121608353 @default.
- W4210369070 hasConcept C126322002 @default.
- W4210369070 hasConcept C141071460 @default.
- W4210369070 hasConcept C143998085 @default.
- W4210369070 hasConcept C188816634 @default.
- W4210369070 hasConcept C197934379 @default.
- W4210369070 hasConcept C2776694085 @default.
- W4210369070 hasConcept C2777740455 @default.
- W4210369070 hasConcept C2778220009 @default.
- W4210369070 hasConcept C2778239845 @default.
- W4210369070 hasConcept C2778424827 @default.
- W4210369070 hasConcept C2779438470 @default.
- W4210369070 hasConcept C2780580887 @default.
- W4210369070 hasConcept C509974204 @default.
- W4210369070 hasConcept C71924100 @default.
- W4210369070 hasConceptScore W4210369070C121608353 @default.
- W4210369070 hasConceptScore W4210369070C126322002 @default.
- W4210369070 hasConceptScore W4210369070C141071460 @default.
- W4210369070 hasConceptScore W4210369070C143998085 @default.
- W4210369070 hasConceptScore W4210369070C188816634 @default.
- W4210369070 hasConceptScore W4210369070C197934379 @default.
- W4210369070 hasConceptScore W4210369070C2776694085 @default.
- W4210369070 hasConceptScore W4210369070C2777740455 @default.
- W4210369070 hasConceptScore W4210369070C2778220009 @default.
- W4210369070 hasConceptScore W4210369070C2778239845 @default.
- W4210369070 hasConceptScore W4210369070C2778424827 @default.
- W4210369070 hasConceptScore W4210369070C2779438470 @default.
- W4210369070 hasConceptScore W4210369070C2780580887 @default.
- W4210369070 hasConceptScore W4210369070C509974204 @default.
- W4210369070 hasConceptScore W4210369070C71924100 @default.
- W4210369070 hasIssue "2" @default.
- W4210369070 hasLocation W42103690701 @default.
- W4210369070 hasOpenAccess W4210369070 @default.
- W4210369070 hasPrimaryLocation W42103690701 @default.
- W4210369070 hasRelatedWork W1997831201 @default.
- W4210369070 hasRelatedWork W2312235271 @default.
- W4210369070 hasRelatedWork W2349271955 @default.
- W4210369070 hasRelatedWork W2376116016 @default.
- W4210369070 hasRelatedWork W2384708512 @default.
- W4210369070 hasRelatedWork W2386230446 @default.
- W4210369070 hasRelatedWork W2404042595 @default.
- W4210369070 hasRelatedWork W2514884906 @default.
- W4210369070 hasRelatedWork W363598932 @default.
- W4210369070 hasRelatedWork W4245694863 @default.
- W4210369070 hasVolume "1" @default.
- W4210369070 isParatext "false" @default.
- W4210369070 isRetracted "false" @default.
- W4210369070 workType "article" @default.